Cambrex Appoints Tom Vadaketh as Executive Vice President and Chief Financial Officer
January 04 2017 - 6:30AM
Cambrex Corporation (NYSE:CBM), a leading manufacturer of small
molecule Active Pharmaceutical Ingredients (APIs), today announced
the hiring of Tom Vadaketh as Executive Vice President and Chief
Financial Officer, effective January 20, 2017. Greg Sargen,
CFO at Cambrex, will transition to a newly-created role, Executive
Vice President, Corporate Development and Strategy. In his
new role, Mr. Sargen will assume responsibility for Corporate
Development and Strategy and will continue to report directly to
Steven M. Klosk, President and Chief Executive Officer.
“We are excited to welcome Tom. He has an
impressive track record and brings a wide variety of experiences
across all financial disciplines to Cambrex,” said Mr. Klosk.
“I am confident that Tom’s experience in senior corporate
roles, especially with manufacturing organizations and facilities,
will be invaluable to Cambrex. Tom and Greg will work closely
together to ensure a seamless transition.”
“2016 has been our sixth consecutive year of
strong organic growth, and we have invested well over $200 million
in internal expansions during that time. As we look to the future,
we recognize the need to complement our organic efforts with
external opportunities,” continued Mr. Klosk. “Greg has led
the finance team and has been a trusted business partner during his
many years at Cambrex. In his new role, Greg will apply his
business acumen, industry knowledge and intimate knowledge of the
Company to identify and execute on new growth opportunities,
including investment in potential new product categories and
capabilities, as well as mergers and acquisitions.”
Mr. Vadaketh was most recently the CFO of the
Crosby Group, a private equity-owned company and a world leader in
the manufacture of rigging, lifting and material handling
applications. Prior to that, he spent nine years in a variety
of increasingly senior financial positions at Tyco International.
In his last role at Tyco, he served as Vice President,
Finance, Corporate Financial Planning & Analysis and CFO of
Global Products. Prior to his time at Tyco, Mr. Vadaketh
spent 15 years in a variety of senior financial roles at Proctor
& Gamble, where he led several corporate and site financial
functions and initiatives. Tom started his career at Deloitte
and Touche in the United Kingdom, where he earned the Chartered
Accountant designation. He also earned his CPA designation in the
United States. Tom has a Master of Business Administration
(MBA) from the University of Manchester, United Kingdom.
About
CambrexCambrex Corporation is an innovative life
sciences company that provides products, services and technologies
to accelerate the development and commercialization of small
molecule therapeutics. The Company offers Active
Pharmaceutical Ingredients (APIs), advanced intermediates and
enhanced drug delivery products for branded and generic
pharmaceuticals. Development and manufacturing capabilities include
enzymatic biotransformations, high potency APIs, high energy
chemical synthesis and controlled substances. For more
information, please visit www.cambrex.com.
Contact:
Stephanie LaFiura
Investor Relations Associate
Tel: 201-804-3037
Email: stephanie.lafiura@cambrex.com
Cambrex (NYSE:CBM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cambrex (NYSE:CBM)
Historical Stock Chart
From Apr 2023 to Apr 2024